2.6M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Amy Herr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 1,976 | 1,280 | - | - | Stock Option (Right to Buy) | |
| Amy Herr | Director | Sale of securities on an exchange or to another person at price $ 65.96 per share. | 14 Feb 2025 | 1,860 | 1,976 (0%) | 0% | 66.0 | 122,691 | Common Stock |
| Amy Herr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.33 per share. | 14 Feb 2025 | 1,976 | 3,836 (0%) | 0% | 44.3 | 87,596 | Common Stock |
| Amy Herr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 115 | 115 | - | - | Restricted Stock Units | |
| Amy Herr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 344 | 344 | - | - | Stock Option (Right to Buy) | |
| Amy Herr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 2,415 | 2,415 | - | - | Stock Option (Right to Buy) | |
| Amy Herr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 1,040 | 1,040 (0%) | 0% | 0 | Common Stock | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 3,320 | 14,401 (0%) | 0% | 0 | Common Stock | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 3,320 | 0 | - | - | Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.55 per share. | 01 Feb 2025 | 1,109 | 13,292 (0%) | 0% | 73.6 | 81,567 | Common Stock |
| Matthew McManus | President - DGS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 4,620 | 4,620 (0%) | 0% | 0 | Common Stock | |
| Matthew McManus | President - DGS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.55 per share. | 01 Feb 2025 | 1,642 | 2,978 (0%) | 0% | 73.5 | 120,769 | Common Stock |
| Matthew McManus | President - DGS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 4,620 | 9,241 | - | - | Restricted Stock Units | |
| Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.70 per share. | 27 Jan 2025 | 13,392 | 52,396 (0%) | 0% | 37.7 | 504,878 | Common Stock |
| Kim Kelderman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.19 per share. | 27 Jan 2025 | 11,731 | 40,665 (0%) | 0% | 77.2 | 905,533 | Common Stock |
| Kim Kelderman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.95 per share. | 27 Jan 2025 | 1,661 | 39,004 (0%) | 0% | 78.0 | 129,480 | Common Stock |
| Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 13,392 | 0 | - | - | Stock Option (Right to Buy) | |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 13,159 | 13,159 | - | - | Restricted Stock Units | |
| James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 6,475 | 106,610 (0%) | 0% | 75.3 | 487,632 | Common Stock |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 13,159 | 113,085 (0%) | 0% | 0 | Common Stock | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 34,634 | 34,634 | - | - | Restricted Stock Units | |
| Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 2,430 | 39,004 (0%) | 0% | 75.3 | 183,003 | Common Stock |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,912 | 9,911 | - | - | Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 3,270 | 11,081 (0%) | 0% | 75.3 | 246,264 | Common Stock |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,912 | 14,351 (0%) | 0% | 0 | Common Stock | |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 48,196 (0%) | 0% | 0 | Common Stock | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 13,771 (0%) | 0% | 0 | Common Stock | |
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 44,863 (0%) | 0% | 0 | Common Stock | |
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 44,559 (0%) | 0% | 0 | Common Stock | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 7,135 (0%) | 0% | 0 | Common Stock | |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 9,347 (0%) | 0% | 0 | Common Stock | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 13,771 (0%) | 0% | 0 | Common Stock | |
| Judith Klimovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Option (Right to Buy) | |
| Judith Klimovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 2,142 (0%) | 0% | 0 | Common Stock | |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 12 Sep 2024 | 6,000 | 48,608 (0%) | 0% | 23.0 | 137,700 | Common Stock |
| John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.20 per share. | 12 Sep 2024 | 1,874 | 46,734 (0%) | 0% | 73.2 | 137,177 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2024 | 6,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.97 per share. | 29 Aug 2024 | 1,492 | 41,434 (0%) | 0% | 67.0 | 99,919 | Common Stock |
| Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2024 | 1,492 | 115,724 | - | - | Stock Option (Right to Buy) | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 32,417 | 32,417 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 12,031 | 12,031 | - | - | Restricted Stock Units | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 24,062 | 24,062 | - | - | Performance Restricted Stock Units | |
| Kim Kelderman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 69,061 | 69,061 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 25,630 | 25,630 | - | - | Restricted Stock Units | |
| Kim Kelderman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 51,261 | 51,261 | - | - | Performance Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 21,204 | 21,204 | - | - | Stock Options (Right to Buy) | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 7,869 | 7,869 | - | - | Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 15,738 | 15,738 | - | - | Performance Restricted Stock Units | |
| Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 21,320 | 21,320 | - | - | Stock Option (Right to Buy) | |
| Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 7,912 | 7,912 | - | - | Restricted Stock Units | |
| Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 15,818 | 15,818 | - | - | Performance Restricted Stock Units | |
| Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 49 | 1,696 (0%) | 0% | 0 | Common Stock | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 13,488 | 13,488 | - | - | Stock Option (Right to Buy) | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 5,006 | 5,006 | - | - | Restricted Stock Units | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 10,012 | 10,012 | - | - | Performance Restricted Stock Units | |
| Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 49 | 99 | - | - | Restricted Stock Units | |
| Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.93 per share. | 15 Aug 2024 | 15 | 1,681 (0%) | 0% | 74.9 | 1,124 | Common Stock |
| Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 15,825 | 15,825 | - | - | Performance Restricted Stock Units | |
| Robert V. Baumgartner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 08 Aug 2024 | 16,000 | 59,401 (0%) | 0% | 23.0 | 367,200 | Common Stock |
| Robert V. Baumgartner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 16,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 72.10 per share. | 08 Aug 2024 | 16,000 | 43,401 (0%) | 0% | 72.1 | 1,153,664 | Common Stock |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2024 | 53,000 | 53,867 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.35 per share. | 02 Aug 2024 | 36,076 | 99,926 (0%) | 0% | 82.4 | 2,970,859 | Common Stock |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 02 Aug 2024 | 53,000 | 136,002 (0%) | 0% | 31.3 | 1,656,780 | Common Stock |
| Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.70 per share. | 31 Jul 2024 | 14,000 | 49,421 (0%) | 0% | 37.7 | 527,800 | Common Stock |
| Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 14,000 | 13,392 | - | - | Stock Option (Right to Buy) | |
| Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.97 per share. | 31 Jul 2024 | 9,479 | 39,942 (0%) | 0% | 82.0 | 776,994 | Common Stock |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 23 Jul 2024 | 35,000 | 107,284 (0%) | 0% | 31.3 | 1,094,100 | Common Stock |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jul 2024 | 35,000 | 106,867 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.77 per share. | 23 Jul 2024 | 24,282 | 83,002 (0%) | 0% | 77.8 | 1,888,411 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 08 Jul 2024 | 6,000 | 42,608 (0%) | 0% | 23.0 | 137,700 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 6,000 | 6,000 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 4,000 | 12,000 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 83.84 per share. | 14 May 2024 | 4,000 | 36,608 (0%) | 0% | 83.8 | 335,377 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 14 May 2024 | 4,000 | 40,608 (0%) | 0% | 23.0 | 91,800 | Common Stock |
| Judith Klimovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,610 | 1,610 | - | - | Stock Option (Right to Buy) | |
| Judith Klimovsky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 680 | 680 (0%) | 0% | 0 | Common Stock | |
| Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 2,259 | 4,519 | - | - | Restricted Stock Units | |
| Shane Bohnen | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.87 per share. | 03 Apr 2024 | 747 | 1,647 (0%) | 0% | 67.9 | 50,699 | Common Stock |
| Shane Bohnen | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 2,259 | 2,394 (0%) | 0% | - | Common Stock | |
| Roeland Nusse | Director | Sale of securities on an exchange or to another person at price $ 76.98 per share. | 07 Mar 2024 | 10,400 | 43,097 (0%) | 0% | 77.0 | 800,627 | Common Stock |
| Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 2,888 | 2,888 | - | - | Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.54 per share. | 01 Feb 2024 | 1,111 | 7,759 (0%) | 0% | 68.5 | 76,148 | Common Stock |
| Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 13,861 | 13,861 | - | - | Restricted Stock Units | |
| McManus Matthew | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 7,951 | 7,951 | - | - | Stock Option (Right to Buy) | |
| McManus Matthew | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 15,902 | 15,902 | - | - | Stock Option (Right to Buy) | |
| Hippel T. James | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.42 per share. | 19 Dec 2023 | 32,966 | 71,884 (0%) | 0% | 77.4 | 2,552,228 | Common Stock |
| T. James Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.26 per share. | 19 Dec 2023 | 47,289 | 104,850 (0%) | 0% | 31.3 | 1,478,254 | Common Stock |
| T. Hippel James | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 47,289 | 141,867 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 9,423 | 9,423 | - | - | Restricted Stock Units | |
| Kelderman Kim | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 51,890 | 51,890 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 25,945 | 25,945 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 24 Aug 2023 | 2,100 | 21,225 (0%) | 0% | 47.6 | 99,960 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Aug 2023 | 2,100 | 109,536 | - | - | Stock Option (Right to Buy) | |
| Geist William | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 9,074 | 9,074 | - | - | Restricted Stock Units | |
| Kelderman Kim | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 8,873 | 8,873 | - | - | Restricted Stock Units | |
| Bohnen Shane | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 12,924 | 12,924 | - | - | Stock Option (Right to Buy) | |
| Kelderman Kim | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 23,881 | 23,881 | - | - | Stock Options (Right to Buy) | |
| T. Hippel James | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 37,314 | 37,314 | - | - | Stock Options (Right to Buy) | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 4,802 | 4,802 | - | - | Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 24,424 | 24,424 | - | - | Stock Options (Right to Buy) | |
| Hippel James T. | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 13,865 | 13,865 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 17,632 | 1,286,944 (3%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.61 per share. | 15 Aug 2023 | 8,675 | 1,278,269 (3%) | 0% | 84.6 | 733,992 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 59,095 | 59,095 | - | - | Restricted Stock Units | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 12,798 | 12,798 | - | - | Restricted Stock Units | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 34,442 | 34,442 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 45,923 | 45,923 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 29,391 | 29,391 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 22,043 | 22,043 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 8,191 | 8,191 | - | - | Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 30,059 | 30,059 | - | - | Stock Options (Right to Buy) | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 22,544 | 22,544 | - | - | Stock Options (Right to Buy) | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 8,377 | 8,377 | - | - | Restricted Stock Units | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 148 | 148 | - | - | Restricted Stock Units | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 16,302 | 16,302 | - | - | Stock Option (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Aug 2023 | 9,008 | 1,269,312 (3%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 51,516 | 1,310,282 (3%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 31,962 | 1,278,320 (3%) | 0% | 82.2 | 2,626,318 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 51,516 | 0 | - | - | Restricted Stock Units | |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 12,876 | 63,896 (0%) | 0% | 0 | Common Stock | |
| James T. Hippel | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 6,335 | 57,561 (0%) | 0% | 82.2 | 520,547 | Common Stock |
| James T. Hippel | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 12,876 | 0 | - | - | Restricted Stock Units | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 8,060 | 0 | - | - | Restricted Stock Units | |
| Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 4,139 | 19,125 (0%) | 0% | 82.2 | 340,102 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 8,060 | 23,264 (0%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.36 per share. | 21 Jul 2023 | 80,000 | 1,258,766 (3%) | 0% | 88.4 | 7,069,024 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 616,676 | 0 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.63 per share. | 30 Jun 2023 | 390,727 | 1,338,766 (3%) | 1% | 81.6 | 31,895,045 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.65 per share. | 30 Jun 2023 | 616,676 | 1,729,493 (4%) | 1% | 26.6 | 16,434,415 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 83.00 per share. | 07 Jun 2023 | 322 | 1,112,817 (2%) | 0% | 83 | 26,726 | Common Stock |
| John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.88 per share. | 28 Apr 2023 | 4,377 | 34,983 (0%) | 0% | 79.9 | 349,635 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 16,000 | 0 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.85 per share. | 28 Apr 2023 | 16,000 | 39,360 (0%) | 0% | 21.9 | 349,600 | Common Stock |
| Roeland Nusse | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Apr 2023 | 377 | 28,811 (0%) | 0% | 0 | Common Stock | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,928 | 3,928 | - | - | Stock Option (right to buy) | |
| Shane Bohnen | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 6,778 | 6,778 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.65 per share. | 04 Jan 2023 | 407,364 | 1,368,976 (3%) | 1% | 26.7 | 10,856,251 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.39 per share. | 04 Jan 2023 | 255,837 | 1,113,139 (2%) | 0% | 84.4 | 21,590,084 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 407,364 | 616,676 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 5,840 (0%) | 0% | 0 | Common Stock | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 2,671 (0%) | 0% | 0 | Common Stock | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Randolph C. Steer | Director | 27 Oct 2022 | 338 | 5,644 (0%) | 0% | 0 | Common Stock | ||
| Randolph C. Steer | Director | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | ||
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 10,444 (0%) | 0% | 0 | Common Stock | |
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 7,297 (0%) | 0% | 0 | Common Stock | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 1,012 (0%) | 0% | 0 | Common Stock | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 1,565 (0%) | 0% | 0 | Common Stock | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 2,671 (0%) | 0% | 0 | Common Stock | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2022 | 663 | 6,848 | - | - | Stock Option (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 23 Aug 2022 | 663 | 3,801 (0%) | 0% | 150.8 | 99,967 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 6,166 | 6,166 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 1,984 | 1,984 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 300,000 | 300,000 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 13,225 | 13,225 | - | - | Restricted Stock Units | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 11,305 | 11,305 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 2,728 | 2,728 | - | - | Restricted Stock Units | |
| James T. Hippel | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 8,479 | 8,479 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | PRES. DIAGNOSTICS & GENOM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 7,235 | 7,235 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | PRES. DIAGNOSTICS & GENOM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 5,426 | 5,426 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | PRES. DIAGNOSTICS & GENOM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 1,746 | 1,746 | - | - | Restricted Stock Units | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 7,400 | 7,400 | - | - | Stock Options (Right to Buy) | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 5,550 | 5,550 | - | - | Stock Options (Right to Buy) | |
| William Geist | PRESIDENT, PROTEIN SCIENCES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 1,785 | 1,785 | - | - | Restricted Stock Units | |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 385.47 per share. | 10 Aug 2022 | 504 | 5,510 (0%) | 0% | 385.5 | 194,277 | Common Stock |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 380.75 per share. | 10 Aug 2022 | 8 | 5,502 (0%) | 0% | 380.8 | 3,046 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 10 Aug 2022 | 3,400 | 8,006 (0%) | 0% | 66.9 | 227,460 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 3,400 | 0 | - | - | Stock Option (right to buy) | |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 373.99 per share. | 10 Aug 2022 | 900 | 7,106 (0%) | 0% | 374.0 | 336,593 | Common Stock |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 374.90 per share. | 10 Aug 2022 | 100 | 7,006 (0%) | 0% | 374.9 | 37,490 | Common Stock |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 380.15 per share. | 10 Aug 2022 | 992 | 6,014 (0%) | 0% | 380.2 | 377,112 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 177.32 per share. | 08 Aug 2022 | 563 | 6,523 (0%) | 0% | 177.3 | 99,831 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2022 | 563 | 16,562 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 6,290 (0%) | 0% | 0 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 1,969 | 0 | - | - | Restricted Stock Units | |
| Brenda S. Furlow | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 969 | 5,960 (0%) | 0% | 383.0 | 371,098 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 1,969 | 6,929 (0%) | 0% | 0 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 1,330 (0%) | 0% | 0 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 4,960 (0%) | 0% | 0 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Aug 2022 | 1,330 | 1,330 (0%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 16,918 | 251,960 (0%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 11,557 | 240,403 (0%) | 0% | 383.0 | 4,425,984 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 16,937 | 0 | - | - | Restricted Stock Units | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 3,938 | 0 | - | - | Restricted Stock Units | |
| James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 1,938 | 12,755 (0%) | 0% | 383.0 | 742,196 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 3,938 | 14,693 (0%) | 0% | 0 | Common Stock | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 2,363 | 0 | - | - | Restricted Stock Units | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 2,363 | 4,352 (0%) | 0% | 0 | Common Stock | |
| Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 1,214 | 3,138 (0%) | 0% | 383.0 | 464,926 | Common Stock |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2022 | 45,346 | 0 | - | - | Stock Option (right to buy) | |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 28 Jul 2022 | 45,346 | 262,749 (0%) | 0% | 108.5 | 4,919,588 | Common Stock |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 380.76 per share. | 28 Jul 2022 | 27,707 | 235,042 (0%) | 0% | 380.8 | 10,549,717 | Common Stock |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 50,000 | 45,346 | - | - | Stock Option (right to buy) | |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 362.78 per share. | 06 Jul 2022 | 30,935 | 217,403 (0%) | 0% | 362.8 | 11,222,599 | Common Stock |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 06 Jul 2022 | 50,000 | 248,338 (0%) | 0% | 108.5 | 5,424,500 | Common Stock |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 364.31 per share. | 07 Jun 2022 | 1,000 | 4,606 (0%) | 0% | 364.3 | 364,310 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 07 Jun 2022 | 1,000 | 5,606 (0%) | 0% | 66.9 | 66,900 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 600 | 3,400 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 1,000 | 4,000 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 366.09 per share. | 07 Jun 2022 | 600 | 4,606 (0%) | 0% | 366.1 | 219,654 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 07 Jun 2022 | 600 | 5,206 (0%) | 0% | 66.9 | 40,140 | Common Stock |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 5,104 | 95,346 | - | - | Stock Option (right to buy) | |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 365.00 per share. | 07 Jun 2022 | 5,104 | 198,338 (0%) | 0% | 365 | 1,862,960 | Common Stock |
| Charles R. Kummeth | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 07 Jun 2022 | 5,104 | 203,442 (0%) | 0% | 108.5 | 553,733 | Common Stock |
| Robert V. Baumgartner | Director | Purchase of securities on an exchange or from another person at price $ 352.55 per share. | 10 May 2022 | 300 | 10,106 (0%) | 0% | 352.6 | 105,765 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2022 | 1,989 | 7,511 | - | - | Stock Option (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 08 Feb 2022 | 1,989 | 1,989 (0%) | 0% | 150.8 | 299,901 | Common Stock |
| William Geist | President, Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 2,490 | 2,490 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 28 Jan 2022 | 938 | 197,539 (0%) | 0% | 106.6 | 99,981 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 28 Jan 2022 | 799 | 198,338 (0%) | 0% | 125.1 | 99,915 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2022 | 938 | 256,010 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2022 | 799 | 194,771 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 503.76 per share. | 19 Nov 2021 | 100 | 400 (0%) | 0% | 503.8 | 50,376 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 505.78 per share. | 19 Nov 2021 | 400 | 0 (0%) | 0% | 505.8 | 202,313 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2021 | 500 | 2,152 | - | - | Stock Option (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 19 Nov 2021 | 500 | 500 (0%) | 0% | 150.8 | 75,390 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 505.49 per share. | 12 Nov 2021 | 2,535 | 1,719 (0%) | 0% | 505.5 | 1,281,407 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.39 per share. | 12 Nov 2021 | 8,989 | 4,254 (0%) | 0% | 504.4 | 4,533,985 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 503.61 per share. | 12 Nov 2021 | 9,043 | 13,243 (0%) | 0% | 503.6 | 4,554,137 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 502.77 per share. | 12 Nov 2021 | 4,054 | 22,286 (0%) | 0% | 502.8 | 2,038,221 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 505.00 per share. | 12 Nov 2021 | 400 | 26,340 (0%) | 0% | 505.0 | 202,002 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.14 per share. | 12 Nov 2021 | 537 | 26,740 (0%) | 0% | 504.1 | 270,725 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 502.99 per share. | 12 Nov 2021 | 300 | 27,277 (0%) | 0% | 503.0 | 150,897 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.78 per share. | 12 Nov 2021 | 200 | 27,577 (0%) | 0% | 504.8 | 100,956 | Common Stock |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 12 Nov 2021 | 27,159 | 28,477 (0%) | 0% | 125.1 | 3,396,233 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 504.09 per share. | 12 Nov 2021 | 700 | 27,777 (0%) | 0% | 504.1 | 352,860 | Common Stock |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2021 | 799 | 0 | - | - | Stock Options (Right to Buy) | |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2021 | 27,159 | 799 | - | - | Stock Options (Right to Buy) | |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 12 Nov 2021 | 799 | 2,117 (0%) | 0% | 125.1 | 99,915 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 506.24 per share. | 12 Nov 2021 | 401 | 1,318 (0%) | 0% | 506.2 | 203,002 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 200 | 47,389 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 8,822 | 47,589 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.10 per share. | 01 Nov 2021 | 200 | 10,755 (0%) | 0% | 525.1 | 105,020 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 200 | 10,955 (0%) | 0% | 125.1 | 25,010 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 528.55 per share. | 01 Nov 2021 | 943 | 10,755 (0%) | 0% | 528.6 | 498,427 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 527.50 per share. | 01 Nov 2021 | 1,433 | 11,698 (0%) | 0% | 527.5 | 755,903 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 526.50 per share. | 01 Nov 2021 | 2,880 | 13,131 (0%) | 0% | 526.5 | 1,516,321 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.61 per share. | 01 Nov 2021 | 3,566 | 16,011 (0%) | 0% | 525.6 | 1,874,318 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 01 Nov 2021 | 8,822 | 19,577 (0%) | 0% | 125.0 | 1,103,191 | Common Stock |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 4,606 (0%) | 0% | 0 | Common Stock | |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 2,333 (0%) | 0% | 0 | Common Stock | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Randolph C. Steer | Director | 28 Oct 2021 | 194 | 5,306 (0%) | 0% | 0 | Common Stock | ||
| Randolph C. Steer | Director | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | ||
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Options (right to buy) | |
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 9,806 (0%) | 0% | 0 | Common Stock | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 6,959 (0%) | 0% | 0 | Common Stock | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 674 (0%) | 0% | 0 | Common Stock | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Oct 2021 | 662 | 56,411 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.23 per share. | 28 Oct 2021 | 662 | 10,755 (0%) | 0% | 525.2 | 347,704 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 28 Oct 2021 | 662 | 11,417 (0%) | 0% | 125.0 | 82,783 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 525.18 per share. | 28 Oct 2021 | 100 | 10,755 (0%) | 0% | 525.2 | 52,518 | Common Stock |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 1,227 (0%) | 0% | 0 | Common Stock | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 2,333 (0%) | 0% | 0 | Common Stock | |
| Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 529.04 per share. | 22 Sep 2021 | 822 | 0 (0%) | 0% | 529.0 | 434,871 | Common Stock |
| Randolph C. Steer | Director | 07 Sep 2021 | 4,000 | 9,112 (0%) | 0% | 87.4 | 349,560 | Common Stock | |
| Randolph C. Steer | Director | 07 Sep 2021 | 4,000 | 0 | - | - | Stock Option (right to buy) | ||
| Randolph C. Steer | Director | 07 Sep 2021 | 4,000 | 0 | - | - | Stock Option (right to buy) | ||
| Randolph C. Steer | Director | 07 Sep 2021 | 500 | 5,112 (0%) | 0% | 511.5 | 255,725 | Common Stock | |
| Randolph C. Steer | Director | 07 Sep 2021 | 4,600 | 5,612 (0%) | 0% | 510.2 | 2,347,052 | Common Stock | |
| Randolph C. Steer | Director | 07 Sep 2021 | 2,900 | 10,212 (0%) | 0% | 509.3 | 1,477,046 | Common Stock | |
| Randolph C. Steer | Director | 07 Sep 2021 | 4,000 | 13,112 (0%) | 0% | 91.8 | 367,120 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 509.67 per share. | 02 Sep 2021 | 5,295 | 9,196 (0%) | 0% | 509.7 | 2,698,711 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 510.82 per share. | 02 Sep 2021 | 1,576 | 7,620 (0%) | 0% | 510.8 | 805,054 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 6,871 | 9,503 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 02 Sep 2021 | 6,871 | 14,491 (0%) | 0% | 125.1 | 859,219 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 510.78 per share. | 02 Sep 2021 | 42,005 | 196,601 (0%) | 0% | 510.8 | 21,455,314 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 02 Sep 2021 | 73,492 | 238,606 (0%) | 0% | 108.5 | 7,973,147 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 73,492 | 100,450 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 10,000 | 0 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 509.14 per share. | 02 Sep 2021 | 7 | 10,855 (0%) | 0% | 509.1 | 3,564 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 507.22 per share. | 02 Sep 2021 | 9,993 | 10,862 (0%) | 0% | 507.2 | 5,068,600 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 02 Sep 2021 | 10,000 | 20,855 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 503.07 per share. | 31 Aug 2021 | 1,538 | 1,318 (0%) | 0% | 503.1 | 773,728 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 506.12 per share. | 31 Aug 2021 | 3,108 | 7,620 (0%) | 0% | 506.1 | 1,573,011 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 505.26 per share. | 31 Aug 2021 | 1,569 | 10,728 (0%) | 0% | 505.3 | 792,755 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 503.24 per share. | 31 Aug 2021 | 323 | 12,297 (0%) | 0% | 503.2 | 162,546 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 31 Aug 2021 | 5,000 | 12,620 (0%) | 0% | 125.1 | 625,250 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2021 | 5,000 | 16,374 | - | - | Stock Options (Right to Buy) | |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 481.77 per share. | 23 Aug 2021 | 299 | 13,313 (0%) | 0% | 481.8 | 144,050 | Common Stock |
| Robert V. Baumgartner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 4,000 | 0 | - | - | Stock Options (right to buy) | |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 487.88 per share. | 23 Aug 2021 | 100 | 9,612 (0%) | 0% | 487.9 | 48,788 | Common Stock |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 487.10 per share. | 23 Aug 2021 | 800 | 9,712 (0%) | 0% | 487.1 | 389,682 | Common Stock |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 486.25 per share. | 23 Aug 2021 | 1,600 | 10,512 (0%) | 0% | 486.3 | 778,004 | Common Stock |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 485.02 per share. | 23 Aug 2021 | 600 | 12,112 (0%) | 0% | 485.0 | 291,015 | Common Stock |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 483.60 per share. | 23 Aug 2021 | 601 | 12,712 (0%) | 0% | 483.6 | 290,643 | Common Stock |
| Robert V. Baumgartner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.39 per share. | 23 Aug 2021 | 4,000 | 13,612 (0%) | 0% | 87.4 | 349,560 | Common Stock |
| Roeland Nusse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2021 | 4,000 | 0 | - | - | Stock Option (right to buy) | |
| Roeland Nusse | Director | Sale of securities on an exchange or to another person at price $ 481.52 per share. | 23 Aug 2021 | 4,000 | 6,765 (0%) | 0% | 481.5 | 1,926,065 | Common Stock |
| Roeland Nusse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.35 per share. | 23 Aug 2021 | 4,000 | 10,765 (0%) | 0% | 70.4 | 281,400 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 799 | 8,704 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2021 | 3,538 | 0 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 475.05 per share. | 19 Aug 2021 | 600 | 7,620 (0%) | 0% | 475.1 | 285,032 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 474.12 per share. | 19 Aug 2021 | 1,838 | 8,220 (0%) | 0% | 474.1 | 871,427 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 473.08 per share. | 19 Aug 2021 | 1,100 | 10,058 (0%) | 0% | 473.1 | 520,391 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 19 Aug 2021 | 799 | 11,158 (0%) | 0% | 125.1 | 99,915 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 19 Aug 2021 | 3,538 | 10,359 (0%) | 0% | 106.6 | 377,115 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2021 | 921 | 173,942 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 108.49 per share. | 11 Aug 2021 | 921 | 165,114 (0%) | 0% | 108.5 | 99,919 | Common Stock |
| N. David Eansor | President-Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,556 | 1,556 | - | - | Restricted Stock Units | |
| N. David Eansor | President-Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 6,080 | 6,080 | - | - | Stock Options (Right to Buy) | |
| N. David Eansor | President-Protein Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 8,107 | 8,107 | - | - | Stock Options (Right to Buy) | |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 2,537 | 0 | - | - | Restricted Stock Units | |
| N. David Eansor | President-Protein Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 999 | 2,856 (0%) | 0% | 481.8 | 481,338 | Common Stock |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 2,537 | 3,855 (0%) | 0% | 0 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,167 | 1,167 | - | - | Restricted Stock Units | |
| Brenda S. Furlow | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 4,560 | 4,560 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 6,080 | 6,080 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 1,374 | 7,498 (0%) | 0% | 0 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 677 | 6,821 (0%) | 0% | 481.8 | 326,192 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 1,374 | 0 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 31,315 | 31,315 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 12,475 | 164,193 (0%) | 0% | 481.8 | 6,010,705 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 16,918 | 176,668 (0%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 5,344 | 159,750 (0%) | 0% | 0 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 20,876 | 20,876 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 8,016 | 8,016 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 16,918 | 0 | - | - | Restricted Stock Units | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 3,383 | 12,520 (0%) | 0% | 0 | Common Stock | |
| James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 1,665 | 10,855 (0%) | 0% | 481.8 | 802,230 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 06 Aug 2021 | 10,000 | 20,855 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 477.69 per share. | 06 Aug 2021 | 5,200 | 15,655 (0%) | 0% | 477.7 | 2,484,002 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 478.58 per share. | 06 Aug 2021 | 1,800 | 13,855 (0%) | 0% | 478.6 | 861,444 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 479.96 per share. | 06 Aug 2021 | 1,300 | 12,555 (0%) | 0% | 480.0 | 623,954 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 480.70 per share. | 06 Aug 2021 | 100 | 12,455 (0%) | 0% | 480.7 | 48,070 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 480.66 per share. | 06 Aug 2021 | 700 | 11,755 (0%) | 0% | 480.7 | 336,462 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 481.61 per share. | 06 Aug 2021 | 300 | 11,455 (0%) | 0% | 481.6 | 144,482 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 483.62 per share. | 06 Aug 2021 | 300 | 11,155 (0%) | 0% | 483.6 | 145,085 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 484.98 per share. | 06 Aug 2021 | 300 | 10,855 (0%) | 0% | 485.0 | 145,494 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 10,000 | 10,000 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 3,383 | 0 | - | - | Restricted Stock Units | |
| James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,945 | 1,945 | - | - | Restricted Stock Units | |
| James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 7,600 | 7,600 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 10,134 | 10,134 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 1,691 | 0 | - | - | Restricted Stock Units | |
| Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 869 | 822 (0%) | 0% | 481.8 | 418,702 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 1,691 | 1,691 (0%) | 0% | 0 | Common Stock | |
| Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 6,486 | 6,486 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 4,864 | 4,864 | - | - | Stock Options (Right to Buy) | |
| Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 460.71 per share. | 12 Jul 2021 | 600 | 9,637 (0%) | 0% | 460.7 | 276,428 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 459.64 per share. | 12 Jul 2021 | 800 | 10,237 (0%) | 0% | 459.6 | 367,712 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 458.81 per share. | 12 Jul 2021 | 1,863 | 11,037 (0%) | 0% | 458.8 | 854,770 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 457.79 per share. | 12 Jul 2021 | 1,136 | 12,900 (0%) | 0% | 457.8 | 520,055 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 456.41 per share. | 12 Jul 2021 | 527 | 14,036 (0%) | 0% | 456.4 | 240,527 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 455.57 per share. | 12 Jul 2021 | 1,773 | 14,563 (0%) | 0% | 455.6 | 807,717 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 454.15 per share. | 12 Jul 2021 | 662 | 16,336 (0%) | 0% | 454.1 | 300,647 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 453.21 per share. | 12 Jul 2021 | 788 | 16,998 (0%) | 0% | 453.2 | 357,126 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 10,000 | 20,000 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 466.44 per share. | 12 Jul 2021 | 100 | 9,137 (0%) | 0% | 466.4 | 46,644 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 463.56 per share. | 12 Jul 2021 | 100 | 9,237 (0%) | 0% | 463.6 | 46,356 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 462.08 per share. | 12 Jul 2021 | 300 | 9,337 (0%) | 0% | 462.1 | 138,625 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 451.95 per share. | 12 Jul 2021 | 751 | 17,786 (0%) | 0% | 452.0 | 339,416 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 451.07 per share. | 12 Jul 2021 | 600 | 18,537 (0%) | 0% | 451.1 | 270,640 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 12 Jul 2021 | 10,000 | 19,137 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 450.39 per share. | 17 Jun 2021 | 1,698 | 158,474 (0%) | 0% | 450.4 | 764,762 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 450.37 per share. | 17 Jun 2021 | 326 | 154,406 (0%) | 0% | 450.4 | 146,821 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 449.09 per share. | 17 Jun 2021 | 2,583 | 154,732 (0%) | 0% | 449.1 | 1,159,999 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 449.35 per share. | 17 Jun 2021 | 6,732 | 160,172 (0%) | 0% | 449.3 | 3,025,024 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 452.13 per share. | 17 Jun 2021 | 109 | 157,315 (0%) | 0% | 452.1 | 49,282 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 451.54 per share. | 17 Jun 2021 | 1,050 | 157,424 (0%) | 0% | 451.5 | 474,117 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 450.10 per share. | 14 Jun 2021 | 349 | 166,904 (0%) | 0% | 450.1 | 157,085 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 449.10 per share. | 14 Jun 2021 | 7,132 | 167,253 (0%) | 0% | 449.1 | 3,202,981 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 433.00 per share. | 09 Jun 2021 | 811 | 0 (0%) | 0% | 433 | 351,163 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 9,942 | 30,000 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 424.59 per share. | 07 Jun 2021 | 310 | 9,137 (0%) | 0% | 424.6 | 131,623 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 423.74 per share. | 07 Jun 2021 | 1,700 | 9,447 (0%) | 0% | 423.7 | 720,357 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 422.81 per share. | 07 Jun 2021 | 2,000 | 11,147 (0%) | 0% | 422.8 | 845,628 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 421.93 per share. | 07 Jun 2021 | 2,396 | 13,147 (0%) | 0% | 421.9 | 1,010,935 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 420.66 per share. | 07 Jun 2021 | 2,029 | 15,543 (0%) | 0% | 420.7 | 853,523 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 419.88 per share. | 07 Jun 2021 | 1,507 | 17,572 (0%) | 0% | 419.9 | 632,765 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 07 Jun 2021 | 9,942 | 19,079 (0%) | 0% | 106.6 | 1,059,718 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 94.35 per share. | 25 May 2021 | 36,849 | 195,690 (0%) | 0% | 94.3 | 3,476,703 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 36,849 | 0 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 420.12 per share. | 25 May 2021 | 21,305 | 174,385 (0%) | 0% | 420.1 | 8,950,657 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 424.00 per share. | 25 May 2021 | 845 | 811 (0%) | 0% | 424 | 358,280 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 1,667 | 0 | - | - | Restricted Stock Units | |
| Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 427.49 per share. | 01 May 2021 | 856 | 1,656 (0%) | 0% | 427.5 | 365,931 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 1,667 | 2,512 (0%) | 0% | - | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 10,997 | 10,997 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 30,000 | 36,849 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 411.00 per share. | 16 Feb 2021 | 17,428 | 158,841 (0%) | 0% | 411 | 7,162,908 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 94.35 per share. | 16 Feb 2021 | 30,000 | 176,269 (0%) | 0% | 94.4 | 2,830,500 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 398.40 per share. | 12 Feb 2021 | 6,674 | 9,450 (0%) | 0% | 398.4 | 2,658,891 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 12 Feb 2021 | 10,000 | 16,124 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 10,000 | 3,538 | - | - | Stock Options (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 399.12 per share. | 12 Feb 2021 | 3,326 | 6,124 (0%) | 0% | 399.1 | 1,327,461 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 12 Feb 2021 | 10,000 | 19,137 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 10,000 | 39,942 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 401.52 per share. | 12 Feb 2021 | 600 | 9,137 (0%) | 0% | 401.5 | 240,911 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 400.32 per share. | 12 Feb 2021 | 9,400 | 9,737 (0%) | 0% | 400.3 | 3,762,998 | Common Stock |
| Roeland Nusse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 1,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Roeland Nusse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Roeland Nusse | Director | Sale of securities on an exchange or to another person at price $ 385.08 per share. | 08 Feb 2021 | 6,000 | 6,765 (0%) | 0% | 385.1 | 2,310,481 | Common Stock |
| Roeland Nusse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 08 Feb 2021 | 5,000 | 12,765 (0%) | 0% | 66.9 | 334,500 | Common Stock |
| Roeland Nusse | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.35 per share. | 08 Feb 2021 | 1,000 | 7,765 (0%) | 0% | 70.4 | 70,350 | Common Stock |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 05 Feb 2021 | 18,819 | 34,251 (0%) | 0% | 106.6 | 2,005,917 | Common Stock |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 18,819 | 0 | - | - | Stock Options (Right to Buy) | |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 14,114 | 0 | - | - | Stock Options (Right to Buy) | |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 385.59 per share. | 05 Feb 2021 | 1,100 | 1,318 (0%) | 0% | 385.6 | 424,151 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 384.15 per share. | 05 Feb 2021 | 1,900 | 2,418 (0%) | 0% | 384.2 | 729,888 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 382.60 per share. | 05 Feb 2021 | 3,700 | 4,318 (0%) | 0% | 382.6 | 1,415,636 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 381.52 per share. | 05 Feb 2021 | 2,900 | 8,018 (0%) | 0% | 381.5 | 1,106,395 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 380.50 per share. | 05 Feb 2021 | 12,833 | 10,918 (0%) | 0% | 380.5 | 4,882,918 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 379.62 per share. | 05 Feb 2021 | 4,500 | 23,751 (0%) | 0% | 379.6 | 1,708,312 | Common Stock |
| N. David Eansor | President-Protein Sciences | Sale of securities on an exchange or to another person at price $ 378.29 per share. | 05 Feb 2021 | 6,000 | 28,251 (0%) | 0% | 378.3 | 2,269,723 | Common Stock |
| N. David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 05 Feb 2021 | 14,114 | 15,432 (0%) | 0% | 106.6 | 1,504,411 | Common Stock |
| Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 388.45 per share. | 05 Feb 2021 | 823 | 845 (0%) | 0% | 388.4 | 319,694 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 344.00 per share. | 15 Jan 2021 | 20,000 | 146,269 (0%) | 0% | 344 | 6,880,000 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 331.61 per share. | 11 Jan 2021 | 700 | 17,637 (0%) | 0% | 331.6 | 232,127 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 330.26 per share. | 11 Jan 2021 | 400 | 18,337 (0%) | 0% | 330.3 | 132,106 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2021 | 10,000 | 49,942 | - | - | Stock Options (Right to Buy) | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 11 Jan 2021 | 10,000 | 19,137 (0%) | 0% | 106.6 | 1,065,900 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 334.98 per share. | 11 Jan 2021 | 2,009 | 9,137 (0%) | 0% | 335.0 | 672,983 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 334.39 per share. | 11 Jan 2021 | 3,990 | 11,146 (0%) | 0% | 334.4 | 1,334,219 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 328.68 per share. | 11 Jan 2021 | 400 | 18,737 (0%) | 0% | 328.7 | 131,472 | Common Stock |
| James T. Hippel | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 333.23 per share. | 11 Jan 2021 | 2,501 | 15,136 (0%) | 0% | 333.2 | 833,415 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 30 Nov 2020 | 10,857 | 16,043 (0%) | 0% | 106.6 | 1,157,248 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 106.59 per share. | 30 Nov 2020 | 938 | 16,981 (0%) | 0% | 106.6 | 99,981 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 301.32 per share. | 30 Nov 2020 | 3,367 | 13,614 (0%) | 0% | 301.3 | 1,014,558 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 302.15 per share. | 30 Nov 2020 | 6,783 | 6,831 (0%) | 0% | 302.1 | 2,049,476 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Sale of securities on an exchange or to another person at price $ 302.82 per share. | 30 Nov 2020 | 707 | 6,124 (0%) | 0% | 302.8 | 214,093 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 938 | 13,538 | - | - | Stock Option (Right to Buy) | |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 10,857 | 0 | - | - | Stock Option (Right to Buy) | |
| Robert V. Baumgartner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2020 | 5,000 | 0 | - | - | Stock Options (right to buy) | |
| Robert V. Baumgartner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 18 Nov 2020 | 5,000 | 14,612 (0%) | 0% | 66.9 | 334,500 | Common Stock |
| Robert V. Baumgartner | Director | Sale of securities on an exchange or to another person at price $ 303.34 per share. | 18 Nov 2020 | 5,000 | 9,612 (0%) | 0% | 303.3 | 1,516,675 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 7,391 | 59,942 | - | - | Stock Option (Right to Buy) | |
| Alpna Seth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 3,125 | 0 | - | - | Stock Option (Right to Buy) | |
| Alpna Seth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 1,898 | 0 | - | - | Stock Option (Right to Buy) | |
| Alpna Seth | Director | Sale of securities on an exchange or to another person at price $ 306.95 per share. | 09 Nov 2020 | 3,665 | 2,139 (0%) | 0% | 307.0 | 1,124,972 | Common Stock |
| Alpna Seth | Director | Sale of securities on an exchange or to another person at price $ 305.74 per share. | 09 Nov 2020 | 1,358 | 5,804 (0%) | 0% | 305.7 | 415,195 | Common Stock |
| Alpna Seth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 125.05 per share. | 09 Nov 2020 | 3,125 | 7,162 (0%) | 0% | 125.0 | 390,781 | Common Stock |
| Alpna Seth | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 179.84 per share. | 09 Nov 2020 | 1,898 | 4,037 (0%) | 0% | 179.8 | 341,336 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2020 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 301.06 per share. | 06 Nov 2020 | 3,100 | 4,412 (0%) | 0% | 301.1 | 933,301 | Common Stock |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 299.84 per share. | 06 Nov 2020 | 450 | 7,512 (0%) | 0% | 299.8 | 134,928 | Common Stock |
| John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 298.98 per share. | 06 Nov 2020 | 1,450 | 7,962 (0%) | 0% | 299.0 | 433,516 | Common Stock |
| John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.35 per share. | 06 Nov 2020 | 5,000 | 9,412 (0%) | 0% | 70.4 | 351,750 | Common Stock |
| Randolph C. Steer | Director | 06 Nov 2020 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Randolph C. Steer | Director | 06 Nov 2020 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Randolph C. Steer | Director | 06 Nov 2020 | 2,535 | 5,112 (0%) | 0% | 304.6 | 772,136 | Common Stock | |
| Randolph C. Steer | Director | 06 Nov 2020 | 975 | 7,647 (0%) | 0% | 304.1 | 296,537 | Common Stock | |
| Randolph C. Steer | Director | 06 Nov 2020 | 1,195 | 8,622 (0%) | 0% | 302.3 | 361,260 | Common Stock | |
| Randolph C. Steer | Director | 06 Nov 2020 | 1,801 | 9,817 (0%) | 0% | 301.8 | 543,506 | Common Stock | |
| Randolph C. Steer | Director | 06 Nov 2020 | 1,771 | 11,618 (0%) | 0% | 300.0 | 531,229 | Common Stock | |
| Randolph C. Steer | Director | 06 Nov 2020 | 1,723 | 13,389 (0%) | 0% | 299.1 | 515,280 | Common Stock | |
| Randolph C. Steer | Director | 06 Nov 2020 | 5,000 | 15,112 (0%) | 0% | 66.9 | 334,500 | Common Stock | |
| Randolph C. Steer | Director | 06 Nov 2020 | 5,000 | 10,112 (0%) | 0% | 70.4 | 351,750 | Common Stock | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2020 | 25,157 | 0 | - | - | Stock Options (Right to Buy) | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 302.47 per share. | 06 Nov 2020 | 15,375 | 171,269 (0%) | 0% | 302.5 | 4,650,476 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.25 per share. | 06 Nov 2020 | 25,157 | 186,644 (0%) | 0% | 86.2 | 2,169,791 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2020 | 8,809 | 0 | - | - | Stock Options (Right to Buy) | |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 391 | 4,412 (0%) | 0% | 0 | Common Stock | |
| John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 391 | 2,139 (0%) | 0% | 0 | Common Stock | |
| Joseph D. Keegan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | |
| Randolph C. Steer | Director | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | ||
| Randolph C. Steer | Director | 29 Oct 2020 | 391 | 5,112 (0%) | 0% | 0 | Common Stock | ||
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 391 | 9,612 (0%) | 0% | 0 | Common Stock | |
| Robert V. Baumgartner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 391 | 12,765 (0%) | 0% | 0 | Common Stock | |
| Roeland Nusse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 391 | 480 (0%) | 0% | 0 | Common Stock | |
| Julie L. Bushman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 391 | 1,033 (0%) | 0% | 0 | Common Stock | |
| Rupert Vessey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 1,507 | 1,507 | - | - | Stock Option (Right to Buy) | |
| Alpna Seth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 391 | 2,139 (0%) | 0% | 0 | Common Stock | |
| David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 2,174 | 2,174 (0%) | 0% | 0 | Common Stock | |
| David Eansor | President-Protein Sciences | Payment of exercise price or tax liability using portion of securities received from the company at price $ 265.76 per share. | 09 Aug 2020 | 856 | 1,318 (0%) | 0% | 265.8 | 227,491 | Common Stock |
| David Eansor | President-Protein Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 2,174 | 0 | - | - | Restricted Stock Units | |
| Brenda S. Furlow | SVP - General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 265.76 per share. | 09 Aug 2020 | 849 | 5,186 (0%) | 0% | 265.8 | 225,630 | Common Stock |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 1,724 | 6,035 (0%) | 0% | 0 | Common Stock | |
| Brenda S. Furlow | SVP - General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 1,724 | 0 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 21,291 | 0 | - | - | Restricted Stock Units | |
| Charles R. Kummeth | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 265.76 per share. | 09 Aug 2020 | 12,287 | 161,487 (0%) | 0% | 265.8 | 3,265,393 | Common Stock |
| Charles R. Kummeth | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 21,291 | 173,774 (0%) | 0% | 0 | Common Stock | |
| James T. Hippel | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 265.76 per share. | 09 Aug 2020 | 2,184 | 9,137 (0%) | 0% | 265.8 | 580,420 | Common Stock |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 4,438 | 0 | - | - | Restricted Stock Units | |
| James T. Hippel | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2020 | 4,438 | 11,321 (0%) | 0% | 0 | Common Stock |